Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUCOBOOST: Intranasal COVID-19 Vaccine vs mRNA Vaccine Booster in Healthy Adults
NCT06821126Phase 2Recruiting
- Sponsor
- ANRS
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LVT-001 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ANRS. Primary endpoints: Proportion of participants experiencing an immediate adverse event at 1.5 hours, Proportion of participants experiencing solicited local reactogenicity at 7 days and 4 more. Started May 2025; status: recruiting.
02
Drugs
LVT-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06821126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821126.